GeneDx Holdings Corp. (WGS) is trading at $90.00, up 12.91 percent, or $10.29 on Tuesday, after the American Academy of Pediatrics updated its guidance to recommend exome and genome sequencing as first-tier tests for children with global developmental delay or intellectual disability.
The stock opened at $83.19 and has traded between $82.01 and $91.00 so far today on the Nasdaq. Volume stands at 1.21 million shares, slightly above the average of 1.13 million. The 52-week range for the stock is $24.91 to $117.75.
The move highlights the value of early genomic testing in improving diagnoses and outcomes, which GeneDx is well positioned to support.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.